In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Serono licenses cancer candidate from Micromet

Executive Summary

Micromet (antibody therapeutics for cancer, inflammation, and autoimmune conditions) and Serono SA have entered into an agreement to further develop Micromet's MT201 (adecatumumab), a fully human monoclonal antibody that targets the epithelial cell adhesion molecule (Ep-CAM) to fight various types of cancer.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies